Navigation Links
Data Presented at AAN Support Potential for Adjunctive use of Intravenous Lacosamide as Short-Term Replacement for Oral Treatment in Partial Epilepsy
Date:4/18/2008

was comparable across all infusion durations (10-, 15- and 30-minute infusions), with headache (5%, 7%, 8%) and dizziness (5%, 6%, 8%) being the most commonly reported. Plasma concentrations were proportional to the actual daily dose given and similar across all infusion duration groups. Intravenous lacosamide was also locally well-tolerated with no serious infusion site reactions. In this study, intravenous lacosamide was administered directly via injection, with no diluent required.

These results support data from an earlier multi-center, double-blind, randomized, inpatient trial that evaluated intravenous lacosamide (200-600 mg/day) as replacement for oral lacosamide in patients with partial onset seizures. In that double-blind trial, intravenous lacosamide showed a similar profile to oral lacosamide when administered as 30- or 60-minute twice daily infusions. The data presented at AAN demonstrated that intravenous lacosamide was also generally well-tolerated at shorter infusion durations.

Intravenous lacosamide was developed as an alternative for patients who temporarily cannot receive oral therapy. Doses of intravenous lacosamide are equivalent to the oral form of the drug and do not require conversion.

About lacosamide: Lacosamide has a dual mode of action and is the first agent of its kind to be clinically studied for the treatment of epilepsy. It selectively enhances slow inactivation of sodium channels and interacts with the neuroplasticity-relevant target-collapsin-response mediator protein-2 (CRMP-2). Lacosamide is also being investigated for its potential effect in reducing diabetic neuropathic pain.

Lacosamide-oral tablet, oral syrup and intravenous formulation-has been filed with the U.S. FDA and the EMEA for use as adjunctive therapy in the treatment of partial onset seizures in adults with epilepsy and is currently under review.

Applications for marketing authorization for lacosamide in epilepsy are supported by da
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Presented at the American Academy of Neurology Show XP13512/GSK1838262 Significantly Improved Symptoms of Moderate-to-Severe Primary Restless Legs Syndrome
2. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
3. Preclinical Study Presented at AACR Annual Meeting Shows Peregrines Anti-PS Immunocytokines Can Generate Protective Immune Responses in a Highly Aggressive Breast Cancer Model
4. Data Presented at AACR Annual Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Tumor Growth By Up to 95% and Halts Metastasis in a Model of Hormone-Refractory Prostate Cancer
5. Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrines anti-PS Vascular Targeting Antibodies
6. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
7. PG500 Series Presented at the AACR Annual Meeting in San Diego
8. Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation
9. Poniard Pharmaceuticals Announces Presentation of Clinical Data From Picoplatin Phase 2 Small Cell Lung Cancer Trial to be Presented at 1st IASLC-ESMO European Lung Cancer Conference
10. Data From Ortho Biotech-Sponsored Studies to be Presented at National Kidney Foundation 2008 Spring Clinical Meetings
11. Senescos Preclinical Pancreatic Islet Data to be Presented at Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... /CNW/ - Eisai Limited is pleased to support the Canadian ... book available in Canada . The comic ... educate children and their parents about epilepsy, the most common ... than 300,000 Canadians. Eisai is guided by a corporate philosophy ... the patient is central – there was a need within ...
(Date:8/21/2014)... , Aug. 21, 2014 /PRNewswire-iReach/ -- ... Equipment, Inc. for the third straight year, No. ... 500|5000, an exclusive ranking of the nation,s fastest-growing ... look at the most important segment of the ... Timberland, Dell, Domino,s Pizza, LinkedIn, Zillow, and many ...
(Date:8/21/2014)...  Seventy-one percent of Americans believe the abuse of strong ... health and safety issue in the United States ... by Repass & Partners, a Cincinnati ... severity of the prescription medication abuse problem and the need ... health situation facing our country," Rex Repass , CEO ...
Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3
... Caremark (NYSE: CVS ) has been named ... by Reputation Institute, in partnership with Forbes Media. The ... RepTrak™ Pulse, a study that measures the 150 largest ... ) Of the companies included in ...
... -- American Oriental Bioengineering, Inc. (NYSE: AOB ) ... (the "NYSE") has notified the Company that it is not ... to timely file its Annual Report on Form 10-K with ... rules, when a Company does not comply with annual report ...
Cached Medicine Technology:CVS Caremark Ranks Among Top 25 Most Reputable Companies in America on Forbes List 2American Oriental Bioengineering Inc. Receives NYSE Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard 2
(Date:8/22/2014)... Buying a policy for different life insurance products can ... coverage types by insurers in the U.S. The Quotes Pros ... the public using its sortable tool at http://quotespros.com/life-insurance.html . ... is expected to promote the discounts and special offerings for ... The system is designed to help an adult locate a ...
(Date:8/22/2014)... 22, 2014 The regional economy is ... is on the grow again. The plant ... summer 2016 to boost production of the popular Highlander ... Indiana’s overall investment to $4 billion. This step allows ... providing additional flexibility to adjust its product mix to ...
(Date:8/22/2014)... August 22, 2014 As the ... http://www.injurybeacon.com/power-morcellator/ ) in uterine surgeries continues to grow, ... companies have decided to limit coverage of uterine ... Telegram, Blue Cross-Blue Shield of Massachusetts will no ... involve morcellation as of September 1, 2014. Other ...
(Date:8/22/2014)... Bcl-2-like protein 11 (BIM) deletion in advanced ... shorter progression free survival (PFS) in epidermal growth ... chemotherapy treated Asian patients. Also, BIM deletion independently ... , The BIM protein can activate the programmed ... in cells. BIM deletion has been detected in ...
(Date:8/22/2014)... Las Vegas, NV (PRWEB) August 22, 2014 ... developed by Dr. Sen and Dr. Samantha Pearson to ... glasses, contacts, and avoid corrective vision surgery by instead ... Shane Michaels, prompting an investigative review. , “There’s ... billions of dollars in revenue each year—it’s because people ...
Breaking Medicine News(10 mins):Health News:Principal Life Insurance Policies Now Quoted for Adults at Insurance Website Online 2Health News:Toyota Indiana Adding 300 Jobs to Build More Highlanders 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 2Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 3Health News:As Power Morcellator Controversy Grows, Bernstein Liebhard LLP Comments on Massachusetts Insurers’ Plans to Limit Coverage of Uterine Morcellation 4Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2
... 17 Addus HomeCare Corporation announced today that it has filed ... Exchange Commission (SEC) relating to a proposed initial public offering of ... and the price range for the offering have not yet been ... be offered by Addus HomeCare Corporation. , ...
... ... (TRACK™) is the first validated, parent-administered asthma-control test for preschool-aged children , ... Wilmington, DE (PRWEB) July 17, ... simple questions to determine if their child,s breathing problems are not under control. AstraZeneca ...
... , , WASHINGTON, July 17 ... nurses today hailed passage of a key amendment in the ... bill this morning that would enable individual states to go ... , Introduced by Rep. Dennis ...
... Could be targets for new treatments, researchers say , FRIDAY, ... genetic variants associated with high blood pressure in black Americans ... treat this major risk factor for heart disease and stroke. ... of PLoS Genetics , is one of a series ...
... , Patient Advocates , Medicare Beneficiaries Visit ... Act, Oppose Additional Cuts to Oxygen Benefit , ... of Congress to support patient-focused reform of the Medicare home oxygen ... (NECA), a national advocacy organization representing patients with chronic obstructive pulmonary ...
... Mass., July 17 The Hanover Insurance Group (NYSE: THG ... availability of a new product offering that can extend homeowners coverage to ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20051031/NEM023LOGO ... is more important than ever as the population of people residing in ...
Cached Medicine News:Health News:Addus HomeCare Corporation Files Registration Statement 2Health News:New Five-Question Test Helps Assess Asthma Control In Children Under Five Years Of Age 2Health News:New Five-Question Test Helps Assess Asthma Control In Children Under Five Years Of Age 3Health News:New Five-Question Test Helps Assess Asthma Control In Children Under Five Years Of Age 4Health News:RNs Praise House Vote to Permit State Single-Payer Laws 2Health News:RNs Praise House Vote to Permit State Single-Payer Laws 3Health News:Five Hypertension Genes Found in Black Americans 2Health News:Five Hypertension Genes Found in Black Americans 3Health News:Home Oxygen Patients and Family Members Visit Capitol Hill to Ask Congress to Protect Medicare Home Oxygen Therapy Benefit 2Health News:The Hanover Launches New Insurance Option to Protect Family Members in Assisted Living Facilities 2Health News:The Hanover Launches New Insurance Option to Protect Family Members in Assisted Living Facilities 3
... of DOA Panel Test is ... in vitro test. It is ... substances in human urine specimens. ... in the point of care ...
... a qualitative immunoassay intended to ... usage of cocaine by detecting ... in human urine at a ... It is for health care,professional ...
The RapidBARBITURATE test is an immunochromatography based one step in vitro test. It is designed for qualitative determination of barbiturates and in human urine specimens above a cut-off level of 3...
... delivers performance, value and safety ... smaller laboratories. It's an affordable, ... small sample volume in both ... a wide operating range and ...
Medicine Products: